pyridoxamine has been researched along with Obesity in 7 studies
Obesity: A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).
| Excerpt | Relevance | Reference |
|---|---|---|
| " Previously, we reported the possible effect of pyridoxamine (K-163), an AGE inhibitor, on improvement of glucose intolerance in type 2 diabetes mellitus KK-A(y)/Ta mice." | 7.75 | Effects of pyridoxamine (K-163) on glucose intolerance and obesity in high-fat diet C57BL/6J mice. ( Funabiki, K; Gohda, T; Hagiwara, S; Horikoshi, S; Ito, T; Matsumoto, M; Murakoshi, M; Ohara, I; Tanimoto, M; Tomino, Y; Yamazaki, T, 2009) |
| "Obesity is associated with an increased risk for the development of type 2 diabetes and vascular complications." | 5.43 | Delayed Intervention With Pyridoxamine Improves Metabolic Function and Prevents Adipose Tissue Inflammation and Insulin Resistance in High-Fat Diet-Induced Obese Mice. ( Brouwers, O; Cleutjens, JP; Gaens, KH; Janssen, BJ; Maessen, DE; Miyata, T; Schalkwijk, CG; Stehouwer, CD; Wouters, K, 2016) |
| "The advanced glycation end product inhibitor pyridoxamine (PYR) and the antioxidant alpha-lipoic acid (LA) interact to ameliorate insulin resistance in obese Zucker rats following short-term (6-week) treatment." | 3.75 | Metabolic interactions of AGE inhibitor pyridoxamine and antioxidant alpha-lipoic acid following 22 weeks of treatment in obese Zucker rats. ( Diehl, CJ; Hasselwander, O; Henriksen, EJ; Lindborg, KA; Matuschek, M; Muellenbach, EM; Teachey, MK, 2009) |
| " Previously, we reported the possible effect of pyridoxamine (K-163), an AGE inhibitor, on improvement of glucose intolerance in type 2 diabetes mellitus KK-A(y)/Ta mice." | 3.75 | Effects of pyridoxamine (K-163) on glucose intolerance and obesity in high-fat diet C57BL/6J mice. ( Funabiki, K; Gohda, T; Hagiwara, S; Horikoshi, S; Ito, T; Matsumoto, M; Murakoshi, M; Ohara, I; Tanimoto, M; Tomino, Y; Yamazaki, T, 2009) |
| "Obesity is associated with an increased risk for the development of type 2 diabetes and vascular complications." | 1.43 | Delayed Intervention With Pyridoxamine Improves Metabolic Function and Prevents Adipose Tissue Inflammation and Insulin Resistance in High-Fat Diet-Induced Obese Mice. ( Brouwers, O; Cleutjens, JP; Gaens, KH; Janssen, BJ; Maessen, DE; Miyata, T; Schalkwijk, CG; Stehouwer, CD; Wouters, K, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 3 (42.86) | 24.3611 |
| 2020's | 2 (28.57) | 2.80 |
| Authors | Studies |
|---|---|
| Van den Eynde, MDG | 1 |
| Houben, AJHM | 1 |
| Scheijen, JLJM | 1 |
| Linkens, AMA | 1 |
| Niessen, PM | 2 |
| Simons, N | 1 |
| Hanssen, NMJ | 1 |
| Kusters, YHAM | 1 |
| Eussen, SJMP | 1 |
| Miyata, T | 2 |
| Stehouwer, CDA | 1 |
| Schalkwijk, CG | 3 |
| Ibrahim, GR | 1 |
| Shah, I | 1 |
| Gariballa, S | 1 |
| Yasin, J | 1 |
| Barker, J | 1 |
| Salman Ashraf, S | 1 |
| Maessen, DE | 1 |
| Brouwers, O | 1 |
| Gaens, KH | 2 |
| Wouters, K | 1 |
| Cleutjens, JP | 1 |
| Janssen, BJ | 1 |
| Stehouwer, CD | 2 |
| Muellenbach, EM | 1 |
| Diehl, CJ | 1 |
| Teachey, MK | 1 |
| Lindborg, KA | 1 |
| Hasselwander, O | 1 |
| Matuschek, M | 1 |
| Henriksen, EJ | 1 |
| Hagiwara, S | 1 |
| Gohda, T | 1 |
| Tanimoto, M | 1 |
| Ito, T | 1 |
| Murakoshi, M | 1 |
| Ohara, I | 1 |
| Yamazaki, T | 1 |
| Matsumoto, M | 1 |
| Horikoshi, S | 1 |
| Funabiki, K | 1 |
| Tomino, Y | 1 |
| Unoki-Kubota, H | 1 |
| Yamagishi, S | 1 |
| Takeuchi, M | 1 |
| Bujo, H | 1 |
| Saito, Y | 1 |
| Rensen, SS | 1 |
| Buurman, WA | 1 |
| Greve, JW | 1 |
| Driessen, A | 1 |
| Wolfs, MG | 1 |
| Hofker, MH | 1 |
| Bloemen, JG | 1 |
| Dejong, CH | 1 |
1 trial available for pyridoxamine and Obesity
| Article | Year |
|---|---|
Pyridoxamine reduces methylglyoxal and markers of glycation and endothelial dysfunction, but does not improve insulin sensitivity or vascular function in abdominally obese individuals: A randomized double-blind placebo-controlled trial.
Topics: Female; Glycation End Products, Advanced; Humans; Insulin Resistance; Magnesium Oxide; Maillard Reac | 2023 |
6 other studies available for pyridoxamine and Obesity
| Article | Year |
|---|---|
Significantly Elevated Levels of Plasma Nicotinamide, Pyridoxal, and Pyridoxamine Phosphate Levels in Obese Emirati Population: A Cross-Sectional Study.
Topics: Adolescent; Adult; Biomarkers; Chromatography, Liquid; Cross-Sectional Studies; Female; Humans; Male | 2020 |
Delayed Intervention With Pyridoxamine Improves Metabolic Function and Prevents Adipose Tissue Inflammation and Insulin Resistance in High-Fat Diet-Induced Obese Mice.
Topics: 3T3-L1 Cells; Adipose Tissue; Animals; Arrhythmias, Cardiac; Cells, Cultured; Diet, High-Fat; Drug A | 2016 |
Metabolic interactions of AGE inhibitor pyridoxamine and antioxidant alpha-lipoic acid following 22 weeks of treatment in obese Zucker rats.
Topics: Animals; Antioxidants; Blood Glucose; Drug Synergism; Female; Glucose Tolerance Test; Glycation End | 2009 |
Effects of pyridoxamine (K-163) on glucose intolerance and obesity in high-fat diet C57BL/6J mice.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Adipokines; Adipose Tissue; Animals; Antioxidants; Cholesterol; Deoxygu | 2009 |
Pyridoxamine, an inhibitor of advanced glycation end product (AGE) formation ameliorates insulin resistance in obese, type 2 diabetic mice.
Topics: Animals; Diabetes Mellitus, Type 2; Glycation End Products, Advanced; Insulin Resistance; Male; Mice | 2010 |
Endogenous formation of Nε-(carboxymethyl)lysine is increased in fatty livers and induces inflammatory markers in an in vitro model of hepatic steatosis.
Topics: Aged; Biomarkers; Biopsy; Cytokines; Enzyme Inhibitors; Fatty Liver; Female; Gene Expression; Guanid | 2012 |